Skip to main content
PMC home page
The Open AIDS Journal logoLink to The Open AIDS Journal
. 2018 May 31;12:38–52. doi: 10.2174/1874613601812010038

Treatment Outcome and Adverse Events of Tenofovir Disoproxil Fumarate Based Regimens as Compared to Zidovudine Based Regimens Among People Living with HIV/AIDS: A Systematic Review and Meta-Analysis of Observational Studies

Adane Teshome Kefale 1,*, Tegene Legese Dadi 1, Tessema Tsehay Biru 1, Teshale Ayele Mega 2
PMCID: PMC6009132  PMID: 30008973

Abstract

Background:

Findings from different studies report inferior clinical and virologic efficacy with TDF/3TC/NVP. But, some studies show that, there was no statistically significant difference in mortality among ZDV and TDF based regimens. The objective of this review was to systematically identify, appraise and synthesize the best available evidence on efficacy and safety of TDF based regimen as compared to ZDV based regimens.

Methods:

A three-step search strategy was used to locate published and unpublished studies. First, an initial limited search of google was undertaken followed by analysis of text words. A second extensive search was undertaken. We searched the PubMed, EMBASE, Google Scholar, Medline, and CINHAL. We did the initial search for articles on July 11-18, 2016, and updated the results on May 13, 2017.Third, the reference lists of all identified articles was searched for additional studies.

Results:

ZDV based regimens had better outcome on prevention of mortality (OR=1.31, 95%CI (1.14, 1.50), I2 = 0%, Chi2 = 2.51), and lower virologic failure (OR = 1.44, 95% CI [1.18, 1.76], chi2 = 5.91, P= 0.003, I2 =83%) while, TDF based regimens were more tolerable (OR=0.15, 95%CI (0.08, 0.30), I2 = 40%, Chi2 = 3.31). The difference in incidence of opportunistic infection is not significant (OR = 0.83, 95% CI [0.52, 1.32], chi2 = 0.11, P= 0.42, I2 =0%).

Conclusion:

There is lower mortality and lower virologic failure in ZDV group, but better safety profile among TDF based regimens.

Keywords: Tenofovir, TDF, Zidovudine, HIV/AIDS, Treatment outcome, ZDV group

1. INTRODUCTION

Although introduction of potent combination Antiretroviral Therapy (cART) into clinical practice had advanced the treatment of Human immunodeficiency virus (HIV) infection [1, 2], the safety and efficacy of these agents was always a concern. The first decade after the advent of effective cART was marked by improving safety, efficacy, tolerability and ease of administration among regimens [3]. This resulted in rapidly emerging scientific understanding of HIV treatment, care and dynamic scale up efforts in resource limited settings with subsequent periodic updates of World Health Organization (WHO) guidelines [4].

Based on evidences of efficacy and safety, the 2010 WHO HIV treatment guideline recommended either tenofovir disoproxil fumarate (TDF) or zidovudine (ZDV) based combinations to be utilized as a first line agents in resource limited settings [5]. Similarly, the 2016 guideline had established TDF/3TC/EFV to be the preferred first line agent, with TDF/lamivudine(3TC)/nevirapine(NVP) or ZDV/3TC/efavirenz(EFV) or NVP as an alternative first line agents [6]. Consequently, many countries made a progress towards initiating first line cART with TDF backbone in HIV naïve patients, although 27% of HIV infected patients in sub-Saharan Africa still received ZDV based regimens [7].

These cART regimens saved hundreds of thousands of lives and provide hope to millions of others [8]. Despite achievements in scaling up access to cART, reduction in HIV related morbidity and mortality accompanied with significant increment in life expectancy of PLWHA [9-11], there were concerns regarding efficacy, safety and tolerability of these agents. Previous studies linked TDF based regimens with nephrotoxicity and reduction in bone mineral [12-14]. Finding from large Nigerian cohort showed inferior clinical and virologic efficacy of TDF when combined with NVP [15]. However, other studies reported that there was no statistically significant difference in all-cause mortality [16] and risk of HIV-1 disease progression or death among ZDV and TDF based regimens [17, 18]. In contrary, TDF based regimens were reported to have durable antiviral response, high genetic barrier to resistance and excellent safety profile [19]. Therefore, it is very crucial to organize the existing fractions of facts to create tangible evidence on comparative safety and efficacy of TDF and ZDV based cART by pooling findings of original studies with systematic review. Thus, this review is aimed to analyize and synthesize data from large observational studies for robust comparisons of efficacy, and safety of TDF based regimens with ZDV counterparts to complement evidences derived from review of randomized clinical trials.

2. METHODS

2.1. Search Strategy and Selection of Articles

The objective of this review was to systematically identify, appraise and synthesize the best available evidences on efficacy and safety of TDF based regimens as compared to ZDV regimens from observational studies.

A pre-search of review databases was conducted in 2017 to determine whether other reviews existed or protocols were under development. The Joanna Briggs Institute Database of Systematic Reviews and Implementation Reports, the Campbell Collaboration library, the National Health Centre Reviews and Dissemination databases, Health Technology Assessment, Evidence of Policy and Practice Information (EPPI-Centre) were searched using keyword and index search terms: HIV, tenofovir, and zidovudine with their MeSH terms. This search strategy described earlier, established that no other systematic reviews of observational studies was conducted on efficacy and safety of TDF based regimens as compared to ZDV based regimens.

A three-step search strategy was used to locate published and unpublished studies. First, an initial limited search of google was undertaken followed by analysis of text words contained in the title and abstract and of the index terms used to describe the articles. A second extensive search was undertaken using all the identified keywords and MeSH terms across all included databases (Appendix I). We searched the PubMed, EMBASE, Google Scholar, Medline, and CINHAL. We did the initial search for articles on July 11-18, 2016, and updated the results on May 13, 2017. Third, the reference lists of all identified articles were searched for additional studies that may have been missed in the electronic search. Studies identified from reference lists searches were assessed for relevance based on the study title. All authors searched each databases on the same day to be consistent. Abstracts and full reports were retrieved for studies that met the inclusion criteria.

2.2. Inclusion Criteria and Study Selection

The predetermined inclusion criteria were:

  1. Studies published in English and conducted till May 13, 2017.

  2. Observational studies

  3. Data presented for comparison of TDF/FTC or 3TC with EFV or NVP and ZDV/FTC or 3TC with EFV or NVP among treatment naive adults infected with HIV-1 (age >=14 years). Lamivudine and emtricitabine (FTC) are considered as comparable in efficacy and safety for this review which is reported from previous studies [20-22], despite some recent literatures reported FTC has some advantages over 3TC [23-25].

  4. There were no restrictions on country of focus.

Study selection was conducted in two stages by all authors independently; first the titles and abstracts of all potential articles were reviewed. Then, articles that passed the preliminary assessment were fully retrieved for detailed critical appraisal by two independent reviewers. In the case of disagreements during appraisal, decision was made through discussion by reviewing articles together.

Besides above mentioned inclusion criteria papers that met the inclusion criteria were critically appraised by two independent reviewers for a single study for methodological validity using standardized critical appraisal instruments from the Joanna Briggs institute meta-analysis of statistical assessment and review instrument (JBI-MAStARI) (Appendix II).

2.3. Data Extraction and Primary Study Outcomes

We extracted data from original articles if it reported at least one of the following outcomes: virologic failure, death, adverse drug events and occurrence of opportunistic infections. Mortality, occurrence of OI and virologic failure (> 1000 HIV RNA copies/ml) were considered as primary outcomes while secondary outcome was adverse drug events. We extracted outcome using the similar data extraction tool of JBI-MAStARI (Appendix III). All results were taken out by two independent reviewers to avoid extraction error. Data about ADEs was extracted as prevalence of adverse effects using WHO definition of ADEs or AIDS clinical trial group classification of drug toxicity or as per the report of author using set up specific criteria for assessment of ADEs. While opportunistic infection was extracted as prevalence according to WHO definition of OIs.

2.4. Data Analysis

Quantitative data were pooled in statistical meta-analysis using RevMan version 5.3 software. We did a fixed-effect meta-analysis to pool the Odds Ratio (OR) of the outcomes of mortality, occurrence of OI, virologic failure and ADEs. Forest plot containing OR, 95% Confidence Intervals (CI), P value, effect size, and, heterogeneity (I2) were constructed. P values less than 0·05 were considered statistically significant. Findings of observational studies which cannot be pooled with meta-analysis were also summarized.

3. RESULT

A total of 1419 articles were identified through databases searching. Of these, 694 articles were excluded as duplicates and by simple observation of titles (Fig. 1).

Fig. (1).

Flow chart of study selection process.

Fig. (1)

Open in a new tab

3.1. Mortality

Data of 21,757 patients from TDF/XTC/EFV or NVP arms and 6,392 patients from ZDV/3TC/EFV or NVP arms was assessed to compare for mortality outcome. A total of 1,129 patients (5.2%) on the TDF arms and 269 patients (4.2%) on the ZDV arms were died (Fig. 2). Patients on TDF based regimens were 1.31 times more likely to die compared to patients on ZDV based regimens (OR: 1.31[1.14, 1.50]), (P=0.0002).

Fig. (2).

Forest Plot of Mortality effect of TDF based regimens as compared to ZDV based regimens among ART naïve HIV-1 infected patients.

Fig. (2)

Open in a new tab

3.2. Virologic Failure (VF)

To compare their effect on viral suppression, data of 1,603 patients treated with TDF based regimens and 4,092 patients with ZDV based regimens from two articles were included. A total of 173 patients (10.8%) on TDF arms experienced VF (Serum Viral RNA >1000 copies/ml) after 6 months of therapy on the regimens (Fig. 3). While, 305 patients (7.5%) who were on ZDV based regimens encountered VF. Patients on TDF based regimens were 1.44 times more likely to experience VF compared to patients on ZDV based regimens (OR: 1.44 [1.18, 1.76]), (P=0.0003).

Fig. (3).

Forest Plot of VF (Viral RNA > copies/ml) in TDF based regimens as compared to ZDV based regimens among ART naïve HIV-1 infected patients.

Fig. (3)

Open in a new tab

3.3. Adverse Drug Events

Data of 228 patients on TDF based regimens and 1,596 patients on ZDV based regimens extracted from three articles was reviewed for comparison of ADEs. A total of 12 patients (5.3%) on TDF arms and 106 patients (6.6%) on ZDV arms experienced at least one ADE (Fig. 4). Occurrence of ADEs was significant in the ZDV based regimens as compared to TDF based regimens (P<0.00001). Patients on the TDF based regimens were 85% less likely to experience ADEs compared to patients on ZDV based regimens (OR: 0.15[0.08, 0.30]).

Fig. (4).

Forest Plot of ADEs occurrence in TDF based regimens as compared to ZDV based regimens among ART naïve HIV-1infected patients.

Fig. (4)

Open in a new tab

In addition to overall analysis, subgroup analysis was also done excluding cross sectional study (Fig. 5). Accordingly, patients on TDF based regimens were 83% less likely to experience ADEs than ZDV based regimens (OR: 0.17[0.08, 0.35]).

Fig. (5).

Forest Plot of ADEs occurrence in TDF based regimens as compared to ZDV based regimens among ART naïve HIV-1 infected patients in subgroup analysis excluding cross sectional study.

Fig. (5)

Open in a new tab

3.4. Opportunistic Infections

Data of 232 patients on TDF based regimens and 269 patients on ZDV based regimens was pooled from two articles to assess occurrence of OIs. A total of 37 patients (15.9%) on TDF arms and 51 patients (19.0%) on ZDV arms developed at least one OI (Fig. 6). Incident of OI between the two arms was not statistically significant (p=0.42).

Fig. (6).

Forest Plot of OI occurrence in TDF based regimens as compared to ZDV based regimens among ART naïve HIV-1infected patients.

Fig. (6)

Open in a new tab

4. DISCUSSION

Getting drug combinations that is superior in its efficacy and safety is important to maintain adherence of PLWHA with cART, better quality and longevity of their life. To answer these questions, we compared TDF based with ZDV based regimens on mortality, ADEs, VF and occurrence of OIs.

To compare these regimens on mortality outcome, four observational studies were included, enrolled a total of 28,149 participants (21,757 on TDF based and 6392 on ZDV based regimens). Zidovudine based regimens had better outcome on prevention of mortality; mortality on TDF based regimens is 1.31 times higher (OR=1.31) (Fig. 4). This finding is in contrast with the review conducted by Dadi TL et al., which shows no significance between the two regimens. This difference might be due to difference in included size of participants and type of studies include in the review. The previous review included only randomized controlled trials, thus, relatively small number of participants (1858 participants) were included [18]. A review by Omeje et al. which included only a single study with participants of 487 also reported that no statistically significant difference in the risk of death between the two groups. Still the difference for this discrepancy might be attributed to limited number of participants derived from a single study which was unable to detect the difference between regimens [16]. Rare events like death should be identified from large participants of observational studies than clinical trials.

Only three studies, enrolled a total of 1824 participants (228 on TDF based and 1596 on ZDV based regimens) were included to compare ADEs. The result of meta-analysis shows TDF based regimens were better tolerated than ZDV counterparts. Patients who took TDF based regimens were 85% more likely to be protected than their counterparts (OR=0.15) (Fig. 6). This difference maintained even when only cohort studies were included in analysis (OR=0.17). Similarly, finding from Omeje et al. reported that statistically more significant adverse events were recorded in the ZDV based regimens than TDF based regimens (9% vs. 4%, P = 0.02) [16]. In addition finding from Dadi TL et al. revealed, TDF based regimens were more tolerable than ZDV based regimen (RR = 1.06) [18]. Those findings implies that TDF based regimens are better tolerated than ZDV based regimens.

Only two studies were pooled for comparison of virologic failure ((serum RNA>1000 copies/ml)), enrolled 5695 participants (1603 on TDF based and 4093 on ZDV based regimens). Accordingly, ZDV based regimens had better outcome (OR = 1.44) (Figure 5) despite studies were heterogeneous (I2=83%). The heterogeneity might be partly explained by the difference in participants enrolled in each study (Table 1).

Table 1.

characteristics of the study included in systematic review.

Author Study Design Study Setting Duration of Follow up Data Source Outcome Measure Participants (type and No) Findings (TDF vs. ZDV)
Scarsi KK 2015 [15] Retrospective cohort Nigeria 105 months Defined cohort Virologic failure (VF) (>1000 copies/ml) Age ≥18yr
(5547)		 159/1484 vs. 298/4063a at 6 month
ART switch not due to VF 256/1484 vs. 622/4063b
Discontinuation* 308/1484 vs. 649/4063a
Labhartd 2015 [26] Cross-sectional Multicentre Data taken from defined cohort Virologic success (<80 copies/ml) Age ≥16yr
(1539)		 930/997 vs. 473/542a
Clinical failure 2.8% vs. 2.7%b
Immunologic failure 4.6% vs. 4.8%b
Velen 2013 [27] Prospective cohort South Africa 37 months ART program Single drug substitution Age ≥17yrs
(2017)		 10/665 vs. 95/1352a
Mortality in PYs 9.2/100PYs vs. 11.1/100PYsa
Loss from care in PYs 9.8/100PYs vs. 9.5/100PYs
Viral suppression (<400 copies/ml at 24 months) 46% in TDF group vs. 42% of participants in ZDV group a
Chi 2010 [28] Retrospective cohort Zambia 18 months ART program Mortality Age >16yrs
(8518)		 332/6284 vs. 90/2234b
Drug substitution in PYs 9.0/100PYs vs. 27.0/100PYsa
Creatinine clearance (Clcr<50ml/min) 73//2759 vs. 5/523a at 6 month while 30/960 vs. 7/294b at 12 month respectively
Program failure** 32.2/100PYs vs. 28.1/100PYsb
Mean change in Clcr (ml/min) -14.7 vs. -12.7b at 6 month and -22.0 vs. -23.7b at 12 month
Chi 2011 [29] Retrospective cohort Zambia 40 months ART program Mortality Age >16yrs
(18866)		 767/15100 vs. 143/3766b
Program failure** 4359/15100 vs. 1412/3766b
Thuppal 2015 [30] Retrospective cohort India 36 months ART program Adverse drug events Adults
(221)		 10/92 vs. 61/129a
Opportunistic infections 17/92 vs. 26/129b
Hospitalization 18/92 vs. 30/129b
Mean change in CD4 (SD) 388(198) vs. 359(220)b
Mean change in BMI (SD) 3.6(3) vs. 1.8 (2.5)a
Amoroso 2012 [31] cross-sectional Multicentre 48 months Defined cohort Viral suppression (<400 copies/ml) after 9 months Age ≥16yrs
(1819)		 597/668 vs. 1008/1151a
Damtew 2014 [32] Retrospective cohort Ethiopia 60 months ART program Mortality Age ≥15yr
(485)		 25/233 vs. 30/252b
Eluwa 2012 [33] Retrospective cohort Nigeria 36 months ART program Adverse drug events Age ≥15yr
(1420)		 1/46 vs. 34/1374a
Ayele T 2017 [34] Retrospective cohort Ethiopia 24 months ART program Mortality Age ≥14yr
(280)		 5/140 vs. 6/140b
Opportunistic infections 20/140 vs. 25/140a
Ayele 2017 [35] Retrospective cohort Ethiopia 24 months ART program Mean change in CD4 (SD) Age ≥14yr
(280)		 321.7(164.8) vs. 299.4(126.1)a
von Braun 2017 [36] Cross-sectional Uganda 24 months Defined cohort VF (>1000 copies/ml) TB/HIV co-infected adults
(Age ≥18yrs)
(148)		 14/119 vs. 7/29c at 6 month
Woldegebriel 2016 [37] Cross-sectional Ethiopia 96 months ART program Adverse drug events Age ≥18yrs
(183)		 1/90 vs. 11/93a
Parkes-ratanshi 2015 [38] Nested cohort Uganda 48 months Defined cohort Anemia (Hgb<6.5g/dl) Adults
(224)		 5/63 vs. 18/161c
Mean change in Hgb (IQR) 0.84(0.51-1.45) vs. 1(0.91-1.52)c at 48 weeks
PrayGod 2017 [39] Cross-sectional Tanzania 40 months Defined cohort prediabetes or diabetes development Malnourished adults (260) 30/135 vs. 29/125b
Baynes 2017 [40] Cross-sectional [] Ethiopia 60 months ART program Serum creatinine (SD) Age>15years
(245)		 0.83(0.36) vs. 0.87(0.38)a
Blood urea nitrogen 11.74(4.17) vs. 14.86(7.53)a
ALT 31.1(4.2) vs. 32.2 (2.3)b
Biset 2016 [41] Cross-sectional Ethiopia 42 months ART program Treatment failure Age ≥18yr
(330)		 11/155 vs. 3/175c
Immunologic failure 10/155 vs. 3/175c
VF (<5000 copies/ml) 10/155 vs. 2/175c
Open in a new tab

*Death, lost follow up, transferred, withdrawal, **death, lost follow up, withdrawal ALT, alanine aminotransferase; BMI, body mass index; IQR, inter quartile range; Hgb, haemoglobin; PYs: person years; SD, standard deviation; VF, Virologic failure, a statistically significant (P<0.05), b not significant, c not reported

This finding is against with previous review conducted by Omeje et al. where more participants on TDF group maintained plasma HIV RNA of <400 copies/ml compared to ZDV based group (84% in the TDF based group and 73% in the ZDV based group; RR 1.16; 95%CI 1.06 to 1.27) [16]. This might be due the difference in viral RNA cut-off points employed (1000 vs. 400 copies/ml) and the confounding effect of NNRTIs where Scarsi et al. used NVP while Von Braun et al. combined with EFV since participants were TB co-infected. However, Spaulding et al. reported that there were no difference between TDF and ZDV containing regimens in terms of virologic response <400 copies/ml (RR=2.04, 95% CI [0.17,24.84]) [4].

Results of two articles were analysed for comparison of occurrence of opportunistic infections. The difference between both regimens is not significant in OI outcome (OR = 0.83, 95% CI [0.52, 1.32]) (Fig. 6). In TDF group, 16% of participants reported OI while 19% in ZDV developed OI. This proportion showed comparable OI outcome between both groups.

4.1. Limitations of The Study

The major limitations of this review is lack of head to head comparison of TDF and ZDV based regimens. There may be also reporting or information bias, since most of articles included in the review were conducted on secondary data. Although we searched for unpublished papers, all studies included are published papers. Thus, there is the possibility of publication bias. Because of the variability of observational study design and different methods of reporting results, there was a difficulty of pooling results. This limit the number of studies and sample size included in some outcomes. In addition variation in length of follow up among studies might affect efficacy and safety profile of each regimens.

CONCLUSION

Pooled data showed superiority of ZDV based regimens in prevention of death and suppression of viral load. However, TDF based regimens were associated with better safety profile. But, no significant difference was observed in OI outcome between groups.

graphic file with name TOAIDJ-12-38_A1.jpg

Open in a new tab

graphic file with name TOAIDJ-12-38_A2.jpg

Open in a new tab

graphic file with name TOAIDJ-12-38_A3.jpg

Open in a new tab

graphic file with name TOAIDJ-12-38_A4.jpg

Open in a new tab

graphic file with name TOAIDJ-12-38_A5.jpg

Open in a new tab

ACKNOWLEDGEMENTS

Declared none.

LIST OF ABBREVIATIONS

ADE

= Adverse Drug Event

AIDS

= Acquired Immunodeficiency Syndrome

ART

= Antiretroviral Therapy

cART

= Combination of Antiretroviral Therapy

CI

= Confidence Intervals

EFV

= Efavirenz

HIV

= Human Immunodefiency Virus

NVP

= Nevirapine

OI

= Opportunistic Infections

PLWHA

= People Living with HIV/AIDS

RR

= Relative Risk

TDF

= Tenofovir Disoproxil Fumarate

TDF/3TC (FTC)/EFV

= Tenofovir Disoproxil Fumarate plus Lamivudine or Emtricitabine plus Efavirenz

TDF/3TC (FTC)/NVP

= Tenofovir Disoproxil Fumarate plus Lamivudine or Emtricitabine plus Nevirapine

VF

= Virologic failure

WHO

= World Health Organization

ZDV

= Zidovudine

ZDV/3TC/NVP

= Zidovudine plus Lamivudine plus nevirapine

ZDV/3TC/EFV

= Zidovudine plus Lamivudine plus Efavirenz

AVAILABILITY OF DATA AND MATERIALS

Data sharing is not applicable to this article as no datasets were generated or analysed during the current review

ROLE OF THE FUNDING SOURCE

There was no funding for this study. The corresponding author had full access to all the data in the study, and had final responsibility for the decision to submit for publication.

AUTHOR’S CONTRIBUTION

ATK did article searching, critical appraisal, data extraction, data analysis, developed manuscript and edited manuscript

TLD did article searching, critical appraisal, data extraction, data analysis, developed manuscript and edited manuscript

TAM did article searching, critical appraisal, data extraction, and data analysis and developed manuscript

TTB did article searching, critical appraisal, data extraction, data analysis and developed manuscript.

CONSENT FOR PUBLICATION

Not applicable.

CONFLICT OF INTEREST

The authors declare no conflict of interest, financial or otherwise.

APPENDIX I: SEARCH STRATEGY FOR PUBMED

((((((((tenofovir) OR (R) -9- (2-phosphonylmethoxypropyl) adenine) OR 9- (2-Phosphonomethoxypropyl) adenine) OR 9- (2-Phosphonylmethoxypropyl) adenine) OR 9- (2-Phosphonylmethoxypropyl) adenine, isomer) OR 9- (2-Phosphonylmethoxypropyl) adenine, (R) isomer t357098) OR 9- (2-Phosphonylmethoxypropyl) adenine, (S) isomer) OR 9-PMPA (tenofovir)) OR tenofovir disoproxil) OR tenofovir disoproxil fumarate) OR viread)) AND (zidovudine) OR 3'-Azido-2',3'-Dideoxythymidine) OR 3'-Azido-3'-deoxythymidine) OR Azidothymidine) OR AZT (Antiviral)) OR AZT Antiviral) OR BW A509U) OR BWA-509U) OR Retrovir)) AND ((((((((((((((((((HIV) OR Acquired Immune Deficiency Syndrome Virus) OR Acquired Immunodeficiency Syndrome Virus) OR AIDS Virus) OR HTLV-III) OR Human Immunodeficiency Virus) OR Human Immunodeficiency Viruses) OR Human T Cell Lymphotropic Virus Type III) OR Human T Lymphotropic Virus Type III) OR Human T-Cell Leukemia Virus Type III) OR Human T-Cell Lymphotropic Virus Type III) OR Human T-Lymphotropic Virus Type III) OR Immunodeficiency Virus, Human) OR Immunodeficiency Viruses, Human) OR LAV-HTLV-III) OR Lymphadenopathy-Associated Virus) OR Virus, Human Immunodeficiency) OR Viruses, Human Immunodeficiency) Filters activated: Clinical Trial, Review, Systematic Reviews, Observational Study, Comparative Study, Meta-Analysis, Humans, English, Adult: 19+ years, Adolescent: 13-18 years.

APPENDIX II: APPRAISAL INSTRUMENT

JBI Critical Appraisal Checklist for Cohort/Case Control Studies

JBI Critical Appraisal Checklist For Cross-Sectional Studies

APPENDIX III: JBI DATA EXTRACTION FORMAT

APPENDIX IV: FOREST PLOT OF VIROLOGIC FAILURE OF TDF VS. AZT BASED REGIMEN IN RANDOM EFFECT MODEL

REFERENCES

  • 1.AIDS.Gov. A Time line of HIV/AIDS. Available from http://www.who.int/tb/publications/global_report/en/ 2016. cited 13 June 2017.
  • 2.Kuritzkes D.R. A fossil record of zidovudine resistance in transmitted isolates of HIV-1. Proc. Natl. Acad. Sci. USA. 2001;98(24):13485–13487. doi: 10.1073/pnas.251559398. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Clayden P., Collins S., Frick M., Harrington M., Horn T., Jefferys R., et al. Drugs, diagnostics, vaccines, preventive technologies, research toward a cure, and immune-based and gene therapies in development: HIV and TB pipeline report. 2016. Available from: http://www.treatmentactiongroup.org/sites/default/files/2016%20Pipeline%20Report%20F ull.pdf cited 13 June 2017.
  • 4.Spaulding A., GW R., Siegfried N. Tenofovir or zidovudine in three-drug combination therapy with one nucleoside reverse transcriptase inhibitor and one non-nucleoside reverse transcriptase inhibitor for initial treatment of HIV infection in antiretroviral-naïve individuals. Cochrane Database Syst. Rev. 2011;(10) doi: 10.1002/14651858.CD008740. [DOI] [PubMed] [Google Scholar]
  • 5.World Health organization. Antiretroviral therapy for HIV infection in adults and adolescents. Geneva. 2010. Available from http://apps.who.int/iris/bitstream/10665/44379/1/9789241599764_eng.pdf. 2017. cited 13 June 2017 . [PubMed]
  • 6.World Health organization. Consolidated Guidelines on The use of antiretroviral drugs for treating and preventing HIV infection. Available from http://apps.who.int/iris/bitstream/10665/208825/1/9789241549684_eng.pdf. 2016. cited 13 June 2017. [PubMed]
  • 7.World Health organization. Antiretroviral medicines in low-and middleE-income countries: Forcasts of global and regional demands for 2014-2018. 2015. Available from http:// apps.who.int/iris/bitstream/10665/179532/1/9789241509152_eng.pdf. 2017. cited 13 June 2017.
  • 8.Tang MW, Kanki PJ, Shafer RW. A review of the virological efficacy of the 4 World Health Organization-recommended tenofovir-containing regimens for initial HIV therapy. . Clin Infect Dis. 2012 Mar 15;54(6):862–875. doi: 10.1093/cid/cir1034. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.World health organization. Global update on the health sector response to HIV. 2014. Available from http://www.who.int/hiv/pub/global-update.pdf. 2017. cited 13 June 2017.
  • 10.UNAIDS. UNAIDS. UNAIDS global AIDS statstics fact sheet. 2016. Available from http://www.unaids.org/sites/default/files/media_asset/UNAIDS_FactSheet_en.pdf. 2016. cited 13 June 2017.
  • 11.High K.P., Brennan-Ing M., Clifford D.B., Cohen M.H., Currier J., Deeks S.G., Deren S., Effros R.B., Gebo K., Goronzy J.J., Justice A.C., Landay A., Levin J., Miotti P.G., Munk R.J., Nass H., Rinaldo C.R., Jr, Shlipak M.G., Tracy R., Valcour V., Vance D.E., Walston J.D., Volberding P., OAR Working Group on HIV and Aging HIV and aging: state of knowledge and areas of critical need for research. A report to the NIH Office of AIDS Research by the HIV and Aging Working Group. J. Acquir. Immune Defic. Syndr. 2012;60(Suppl. 1):S1–S18. doi: 10.1097/QAI.0b013e31825a3668. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Woratanarat K., Kanjanabuch T., Suankratay C. Tenofovir disoproxil fumarate-associated nephrotoxicity in HIV-infected patients: A prospective controlled study. J. Med. Assoc. Thai. 2013;96(4):432–439. [PubMed] [Google Scholar]
  • 13.Fux CA, Simcock M, Wolbers M, Bucher HC, Hirschel B, Opravil M, et al. Tenofovir use is associated with a reduction in calculated glomerular filtration rates in the Swiss HIV Cohort Study. 2007. [PubMed]
  • 14.Woodward C.L.N., Hall A.M., Williams I.G., Madge S., Copas A., Nair D., Edwards S.G., Johnson M.A., Connolly J.O. Tenofovir-associated renal and bone toxicity. HIV Med. 2009;10(8):482–487. doi: 10.1111/j.1468-1293.2009.00716.x. [DOI] [PubMed] [Google Scholar]
  • 15.Scarsi K.K., Eisen G., Darin K.M., Meloni S.T., Rawizza H.E., Tchetgen E.J.T., et al. Superior Effectiveness of Zidovudine Compared With Tenofovir When Combined With Nevirapine-based Antiretroviral Therapy in a Large Nigerian Cohort. Clin. Infect. Dis. 2015;••• doi: 10.1093/cid/civ928. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Omeje I., Okwundu C.I. Effectiveness and safety of first-line tenofovir + emtricitabine + efavirenz for patients with HIV. Cochrane Database Syst. Rev. 2012;2012(2) doi: 10.1002/14651858.CD007276.pub2. [Review]. [DOI] [PubMed] [Google Scholar]
  • 17.Campbell T.B., Smeaton L.M., Kumarasamy N., Flanigan T., Klingman K.L., Firnhaber C., Grinsztejn B., Hosseinipour M.C., Kumwenda J., Lalloo U., Riviere C., Sanchez J., Melo M., Supparatpinyo K., Tripathy S., Martinez A.I., Nair A., Walawander A., Moran L., Chen Y., Snowden W., Rooney J.F., Uy J., Schooley R.T., De Gruttola V., Hakim J.G., PEARLS study team of the ACTG Efficacy and safety of three antiretroviral regimens for initial treatment of HIV-1: A randomized clinical trial in diverse multinational settings. PLoS Med. 2012;9(8):e1001290. doi: 10.1371/journal.pmed.1001290. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Dadi T.L., Kefale A.T., Mega T.A., Kedir M.S., Addo H.A., Biru T.T. Efficacy and Tolerability of Tenofovir Disoproxil Fumarate Based Regimen as Compared to Zidovudine Based Regimens: A Systematic Review and Meta-Analysis. Aids Res. Treat. 2017;2017:5792925. doi: 10.1155/2017/5792925. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Pozniak A.L., Gallant J.E., DeJesus E., Arribas J.R., Gazzard B., Campo R.E., Chen S.S., McColl D., Enejosa J., Toole J.J., Cheng A.K. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: Virologic, immunologic, and morphologic changes-a 96-week analysis. J. Acquir. Immune Defic. Syndr. 2006;43(5):535–540. doi: 10.1097/01.qai.0000245886.51262.67. [DOI] [PubMed] [Google Scholar]
  • 20.Ford N., Shubber Z., Hill A., Vitoria M., Doherty M., Mills E.J., Gray A. Comparative efficacy of Lamivudine and emtricitabine: A systematic review and meta-analysis of randomized trials. PLoS One. 2013;8(11):e79981. doi: 10.1371/journal.pone.0079981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.World Health organization. Technical update on treatment optimization: pharmacological equivalence and clinical interchangeability of lamivudine and emtricitabine: A review of current literature [Internet]. 2012. Available from: http://apps.who.int/iris/handle/10665/70936. 2017. cited 22 August.
  • 22.Benson C.A., van der Horst C., Lamarca A., Haas D.W., McDonald C.K., Steinhart C.R., Rublein J., Quinn J.B., Mondou E., Rousseau F., FTC-303/350 Writing Group A randomized study of emtricitabine and lamivudine in stably suppressed patients with HIV. AIDS. 2004;18(17):2269–2276. doi: 10.1097/00002030-200411190-00007. [DOI] [PubMed] [Google Scholar]
  • 23.Rokx C., Fibriani A., van de Vijver D.A.M.C., Verbon A., Schutten M., Gras L., Rijnders B.J., AIDS Therapy Evaluation in the Netherlands National Observational Cohort Increased virological failure in naive HIV-1-infected patients taking lamivudine compared with emtricitabine in combination with tenofovir and efavirenz or nevirapine in the Dutch nationwide ATHENA cohort. Clin. Infect. Dis. 2015;60(1):143–153. doi: 10.1093/cid/ciu763. [DOI] [PubMed] [Google Scholar]
  • 24.Swartz J.E., Vandekerckhove L., Ammerlaan H., de Vries A.C., Begovac J., Bierman W.F.W., Boucher C.A., van der Ende M.E., Grossman Z., Kaiser R., Levy I., Mudrikova T., Paredes R., Perez-Bercoff D., Pronk M., Richter C., Schmit J.C., Vercauteren J., Zazzi M., Židovec Lepej S., De Luca A., Wensing A.M., European Society for translational Antiviral Research (ESAR) Efficacy of tenofovir and efavirenz in combination with lamivudine or emtricitabine in antiretroviral-naive patients in Europe. J. Antimicrob. Chemother. 2015;70(6):1850–1857. doi: 10.1093/jac/dkv033. [DOI] [PubMed] [Google Scholar]
  • 25.Rokx C., Fibriani A., van de Vijver D., Verbon A., Schutten M., Gras L., et al. Journal of the International AIDS Society. 2014. More virological failure with lamivudine than emtricitabine in efavirenz and nevirapine regimens in the Dutch nationwide HIV Cohort. p. 19491. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Lejone T.I., Ringera I., Puga D., Glass T.R., Klimkait T. Is zidovudine first-line therapy virologically comparable to tenofovir in resource-limited settings? Trop. J. Pharm. Res. 2016;20(7):914–918. doi: 10.1111/tmi.12509. [DOI] [PubMed] [Google Scholar]
  • 27.Velen K., Lewis J.J., Charalambous S., Grant A.D., Churchyard G.J., Hoffmann C.J. Comparison of tenofovir, zidovudine, or stavudine as part of first-line antiretroviral therapy in a resource-limited-setting: a cohort study. PLoS One. 2013;8(5):e64459. doi: 10.1371/journal.pone.0064459. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Chi B.H., Mwango A., Giganti M., Mulenga L.B., Tambatamba-Chapula B., Reid S.E., Bolton-Moore C., Chintu N., Mulenga P.L., Stringer E.M., Sheneberger R., Mwaba P., Stringer J.S. Early clinical and programmatic outcomes with tenofovir-based antiretroviral therapy in Zambia. J. Acquir. Immune Defic. Syndr. 2010;54(1):63–70. doi: 10.1097/QAI.0b013e3181c6c65c. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Chi B.H., Mwango A., Giganti M.J., Sikazwe I., Moyo C., Schuttner L., Mulenga L.B., Bolton-Moore C., Chintu N.T., Sheneberger R., Stringer E.M., Stringer J.S. Comparative outcomes of tenofovir-based and zidovudine-based antiretroviral therapy regimens in Lusaka, Zambia. J. Acquir. Immune Defic. Syndr. 2011;58(5):475–481. doi: 10.1097/QAI.0b013e31823058a3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Thuppal S.V., Wanke C.A., Noubary F., Cohen J.T., Mwamburi M., Ooriapdickal A.C., Muliyil J., Kang G., Varghese G.M., Rupali P., Karthik R., Sathasivam R., Clarance P., Pulimood S.A., Peter D., George L. Toxicity and clinical outcomes in patients with HIV on zidovudine and tenofovir based regimens: A retrospective cohort study. Trans. R. Soc. Trop. Med. Hyg. 2015;109(6):379–385. doi: 10.1093/trstmh/trv016. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Amoroso A., Etienne-Mesubi M., Edozien A., Ojoo S., Sheneberger R., Obiefune M., Hossain M.B., Stafford K., Redfield R.R. Treatment outcomes of recommended first-line antiretroviral regimens in resource-limited clinics. J. Acquir. Immune Defic. Syndr. 2012;60(3):314–320. doi: 10.1097/QAI.0b013e31824e5256. [DOI] [PubMed] [Google Scholar]
  • 32.Damtew B., Mengistie B., Alemayehu T. Survival and Determinants of Mortality in Adult HIV/AIDS Patients Initiating Antiretroviral Therapy in Somali Region, Eastern Ethiopia. J. AIDS Clin. Res. 2014;5(7):5–10. doi: 10.4172/2155-6113.1000327. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Eluwa G.I., Badru T., Agu K.A., Akpoigbe K.J., Chabikuli O., Hamelmann C. Adverse drug reactions to antiretroviral therapy (ARVs): Incidence, type and risk factors in Nigeria. BMC Clin. Pharmacol. 2012;12(1):7. doi: 10.1186/1472-6904-12-7. [Internet]. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Ayele T., Jarso H., Mamo G. Clinical Outcomes of Tenofovir Versus Zidovudine-based Regimens Among People Living with HIV/AIDS: a Two Years Retrospective Cohort Study. Open AIDS J. 2017;11:1–11. doi: 10.2174/1874613601711010001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Ayele T., Jarso H., Mamo G. Immunological outcomes of Tenofovir versus Zidovudine-based regimens among people living with HIV/AIDS: A two years retrospective cohort study. AIDS Res. Ther. 2017;14(1):5. doi: 10.1186/s12981-017-0132-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.von Braun A., Sekaggya-Wiltshire C., Scherrer A.U., Magambo B., Kambugu A., Fehr J., Castelnuovo B. Early virological failure and HIV drug resistance in Ugandan adults co-infected with tuberculosis. AIDS Res. Ther. 2017;14(1):1–6. doi: 10.1186/s12981-016-0128-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Weldegebreal F., Mitiku H., Teklemariam Z. Magnitude of adverse drug reaction and associated factors among HIV-infected adults on antiretroviral therapy in Hiwot Fana specialized university hospital, eastern Ethiopia. Pan Afr. Med. J. 2016;24(255):255. doi: 10.11604/pamj.2016.24.255.8356. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Parkes-Ratanshi R., Katende D., Levin J., Wakeham K., Heiner G., Kamali A., Lalloo D.G. Development of severe anaemia and changes in Haemoglobin (Hb) in a cohort of HIV infected Ugandan Adults receiving Zidovudine, Stavudine and Tenofovir containing antiretroviral regimens. J. Int. Assoc. Provid. AIDS Care. 2015;14(5):455–462. doi: 10.1177/2325957414557264. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.PrayGod G., Changalucha J., Kapiga S., Peck R., Todd J., Filteau S. Dysglycemia associations with adipose tissue among HIV-infected patients after 2 years of antiretroviral therapy in Mwanza: A follow-up cross-sectional study. BMC Infect. Dis. 2017;17(1):103. doi: 10.1186/s12879-017-2209-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Baynes H.W., Tegene B., Gebremichael M., Birhane G., Kedir W., Biadgo B. Assessment of the effect of antiretroviral therapy on renal and liver functions among HIV-infected patients : a retrospective study. HIV /AIDS- Res. Palliat. Care. 2017;9:1–7. doi: 10.2147/HIV.S120979. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Tsegaye Y., Biset M.A., Kumilachew D., Belay A., Getu S., Teju D., et al. First-line antiretroviral treatment failure and associated factors in HIV patients at the University of Gondar Teaching Hospital, Gondar, Northwest Ethiopia. HIV /AIDS- Res. Palliat. Care. 2016;8:141–146. doi: 10.2147/HIV.S112048. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Availability Statement

Data sharing is not applicable to this article as no datasets were generated or analysed during the current review

Articles from The Open AIDS Journal are provided here courtesy of Bentham Science Publishers

RESOURCES